An observational study in Subdural Hematoma, sponsored by Assiut University. Not yet recruiting at 2 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Assiut University · Observational
To evaluate the outcome of one burrhole evacuation for subdural hematoma and it has the same result of traditional two burrhole
Types of Subdural hematoma(18.19)
1- Acute: present within 48-72 hours of injury. 2. Sub-acute: manifest itself between 3-20 day. 3- Chronic (CH): produce symptoms from 3 weeks to several months after injury Risk Factors: (7.8.9.10.11.12)
Advanced age: The elderly are at risk due to:
CT brain (14.15)
Management : (1.6.16.17)
44 studies on the registry are indexed under Hematoma, Subdural; 15 are open to participants now.
This study's planned enrollment of 35 is below the median of 167 across 11 observational studies indexed under Hematoma, Subdural.
Browse Hematoma, Subdural studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Both sex Adult obove 18 years old
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evacuation for subdural hematoma by one burrhole
ClinicalEvaluation of evacuation for subdural hematoma by one burrhole
* glasgo coma scale, * neurological deficit, * clinical symptoms (seizures) .
Time frame: 72 hours post operative
Radiological evaluation for outcome
Nearly gross total evacuation according to confirmation by postoperative CT brain
Time frame: 72 hours post operative
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.